EdgarLookup

Surgery Partners, Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Surgery Partners, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-16.9%
Profit Margin
Net income ÷ revenue
-1%
Return on Assets
Net income ÷ assets
+248.1%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2017 Dec 31, 2017 $460.35M Mar 16, 2018
FY2017 Sep 30, 2017 $132.26M Mar 16, 2018
FY2016 Dec 31, 2016 $306.00M Mar 10, 2017
FY2016 Sep 30, 2016 $282.68M Mar 10, 2017
FY2016 Jun 30, 2016 $289.68M Mar 10, 2017
FY2016 Mar 31, 2016 $267.07M Mar 10, 2017
FY2016 Dec 31, 2015 $263.32M Mar 10, 2017
FY2016 Sep 30, 2015 $239.60M Mar 10, 2017
FY2016 Jun 30, 2015 $232.83M Mar 10, 2017
FY2016 Mar 31, 2015 $224.14M Mar 10, 2017

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($77.90M) Mar 2, 2026
FY2025 Dec 31, 2024 ($168.10M) Mar 2, 2026
FY2025 Dec 31, 2023 ($11.90M) Mar 2, 2026
FY2024 Dec 31, 2022 ($54.60M) Mar 7, 2025
FY2023 Dec 31, 2021 ($70.90M) Feb 26, 2024
FY2022 Dec 31, 2020 ($116.10M) Mar 1, 2023
FY2019 Dec 31, 2019 ($19.20M) Mar 13, 2020
FY2019 Sep 30, 2019 ($15.70M) Mar 13, 2020
FY2019 Jun 30, 2019 ($19.80M) Mar 13, 2020
FY2019 Mar 31, 2019 ($20.10M) Mar 13, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $389.50M Mar 2, 2026
FY2025 Dec 31, 2024 $348.80M Mar 2, 2026
FY2025 Dec 31, 2023 $328.00M Mar 2, 2026
FY2024 Dec 31, 2022 $345.20M Mar 7, 2025
FY2023 Dec 31, 2021 $302.20M Feb 26, 2024
FY2022 Dec 31, 2020 $183.00M Mar 1, 2023
FY2021 Dec 31, 2019 $235.90M Mar 1, 2022
FY2020 Dec 31, 2018 $77.80M Mar 10, 2021
FY2019 Dec 31, 2017 $92.30M Mar 13, 2020
FY2019 Aug 31, 2017 $66.00M Mar 13, 2020

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $274.30M Mar 2, 2026
FY2025 Dec 31, 2024 $300.10M Mar 2, 2026
FY2025 Dec 31, 2023 $293.80M Mar 2, 2026
FY2024 Dec 31, 2022 $158.80M Mar 7, 2025
FY2023 Dec 31, 2021 $87.10M Feb 26, 2024
FY2022 Dec 31, 2020 $246.90M Mar 1, 2023
FY2021 Dec 31, 2019 $129.50M Mar 1, 2022
FY2020 Dec 31, 2018 $144.60M Mar 10, 2021
FY2019 Dec 31, 2017 $53.20M Mar 13, 2020
FY2019 Aug 31, 2017 $67.70M Mar 13, 2020

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $78.70M Mar 2, 2026
FY2025 Dec 31, 2024 $90.40M Mar 2, 2026
FY2025 Dec 31, 2023 $88.80M Mar 2, 2026
FY2024 Dec 31, 2022 $80.60M Mar 7, 2025
FY2023 Dec 31, 2021 $57.60M Feb 26, 2024
FY2022 Dec 31, 2020 $42.90M Mar 1, 2023
FY2021 Dec 31, 2019 $73.60M Mar 1, 2022
FY2020 Dec 31, 2018 $39.80M Mar 10, 2021
FY2019 Dec 31, 2017 $10.80M Mar 13, 2020
FY2019 Aug 31, 2017 $18.80M Mar 13, 2020

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $8.12B Mar 2, 2026
FY2025 Dec 31, 2024 $7.89B Mar 2, 2026
FY2024 Dec 31, 2023 $6.88B Mar 7, 2025
FY2023 Dec 31, 2022 $6.68B Feb 26, 2024
FY2022 Dec 31, 2021 $6.12B Mar 1, 2023
FY2021 Dec 31, 2020 $5.41B Mar 1, 2022
FY2020 Dec 31, 2019 $5.02B Mar 10, 2021
FY2019 Dec 31, 2018 $4.68B Mar 13, 2020
FY2018 Dec 31, 2017 $4.62B Mar 15, 2019
FY2016 Dec 31, 2016 $2.30B Mar 10, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.71B Mar 2, 2026
FY2025 Dec 31, 2024 $1.79B Mar 2, 2026
FY2024 Dec 31, 2023 $1.99B Mar 7, 2025
FY2023 Dec 31, 2022 $2.00B Feb 26, 2024
FY2022 Dec 31, 2021 $1.09B Mar 1, 2023
FY2021 Dec 31, 2020 $115.60M Mar 1, 2022
FY2020 Dec 31, 2019 $296.80M Mar 10, 2021
FY2019 Dec 31, 2018 $404.60M Mar 13, 2020
FY2018 Dec 31, 2017 $654.73M Mar 15, 2019
FY2016 Dec 31, 2016 $9.68M Mar 10, 2017

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $5.19B Mar 2, 2026
FY2025 Dec 31, 2024 $5.07B Mar 2, 2026
FY2025 Dec 31, 2023 $4.33B Mar 2, 2026
FY2024 Dec 31, 2022 $4.14B Mar 7, 2025
FY2023 Dec 31, 2021 $3.91B Feb 26, 2024
FY2022 Dec 31, 2020 $3.47B Mar 1, 2023
FY2021 Dec 31, 2019 $3.40B Mar 1, 2022
FY2020 Dec 31, 2018 $3.38B Mar 10, 2021
FY2019 Dec 31, 2017 $3.35B Mar 13, 2020
FY2018 Aug 31, 2017 $3.27B Mar 15, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($815.20M) Mar 2, 2026
FY2025 Dec 31, 2024 ($737.30M) Mar 2, 2026
FY2024 Dec 31, 2023 ($569.20M) Mar 7, 2025
FY2023 Dec 31, 2022 ($557.30M) Feb 26, 2024
FY2022 Dec 31, 2021 ($502.70M) Mar 1, 2023
FY2021 Dec 31, 2020 ($431.80M) Mar 1, 2022
FY2020 Dec 31, 2019 ($315.70M) Mar 10, 2021
FY2019 Dec 31, 2018 ($247.00M) Mar 13, 2020
FY2018 Dec 31, 2017 ($41.32M) Mar 15, 2019
FY2016 Dec 31, 2016 ($311.35M) Mar 10, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $239.90M Mar 2, 2026
FY2025 Dec 31, 2024 $269.50M Mar 2, 2026
FY2024 Dec 31, 2023 $195.90M Mar 7, 2025
FY2023 Dec 31, 2022 $282.90M Feb 26, 2024
FY2022 Dec 31, 2021 $389.90M Mar 1, 2023
FY2021 Dec 31, 2020 $317.90M Mar 1, 2022
FY2020 Dec 31, 2019 $92.70M Mar 10, 2021
FY2019 Dec 31, 2018 $184.30M Mar 13, 2020
FY2018 Dec 31, 2017 $174.91M Mar 15, 2019
FY2017 Aug 31, 2017 $214.21M Mar 16, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $3.74B Mar 2, 2026
FY2024 Dec 31, 2024 $3.40B Mar 7, 2025
FY2023 Dec 31, 2023 $2.80B Feb 26, 2024
FY2022 Dec 31, 2022 $2.63B Mar 1, 2023
FY2021 Dec 31, 2021 $2.96B Mar 1, 2022
FY2020 Dec 31, 2020 $2.88B Mar 10, 2021
FY2019 Dec 31, 2019 $2.60B Mar 13, 2020
FY2018 Dec 31, 2018 $2.33B Mar 15, 2019
FY2017 Dec 31, 2017 $2.19B Mar 16, 2018
FY2016 Dec 31, 2016 $1.47B Mar 10, 2017

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 2, 2026
FY2025 Dec 31, 2024 (1) Mar 2, 2026
FY2025 Dec 31, 2023 0 Mar 2, 2026
FY2024 Dec 31, 2022 0 Mar 7, 2025
FY2023 Dec 31, 2021 (1) Feb 26, 2024
FY2022 Dec 31, 2020 (3) Mar 1, 2023
FY2019 Dec 31, 2019 0 Mar 13, 2020
FY2019 Sep 30, 2019 0 Mar 13, 2020
FY2019 Jun 30, 2019 0 Mar 13, 2020
FY2019 Mar 31, 2019 0 Mar 13, 2020

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 2, 2026
FY2025 Dec 31, 2024 (1) Mar 2, 2026
FY2025 Dec 31, 2023 0 Mar 2, 2026
FY2024 Dec 31, 2022 0 Mar 7, 2025
FY2023 Dec 31, 2021 (1) Feb 26, 2024
FY2022 Dec 31, 2020 (3) Mar 1, 2023
FY2019 Dec 31, 2019 0 Mar 13, 2020
FY2019 Sep 30, 2019 0 Mar 13, 2020
FY2019 Jun 30, 2019 0 Mar 13, 2020
FY2019 Mar 31, 2019 0 Mar 13, 2020

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 129.32M Mar 2, 2026
FY2025 Dec 31, 2024 127.11M Mar 2, 2026
FY2024 Dec 31, 2023 126.59M Mar 7, 2025
FY2023 Dec 31, 2022 125.96M Feb 26, 2024
FY2022 Dec 31, 2021 89.33M Mar 1, 2023
FY2021 Dec 31, 2020 50.46M Mar 1, 2022
FY2020 Dec 31, 2019 49.30M Mar 10, 2021
FY2019 Dec 31, 2018 48.87M Mar 13, 2020
FY2018 Dec 31, 2017 48.69M Mar 15, 2019
FY2016 Dec 31, 2016 48.49M Mar 10, 2017